Dr. Elizabeth A. Brem, MD

Dr. Brem practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Brem's NPI, 1578883781, was assigned on June 10, 2010. Dr. Brem graduated from Jacobs School of Medicine and Biomedical Sciences in 2010. Dr. Brem holds California license 143521.

Dr. Brem's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Brem's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brem practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Brem's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Brem is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Brem's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists acute skin infection, bronchitis, cellulitis, chronic anemia, deep vein thrombosis (DVT), fluid and electrolyte imbalances, immune deficiency disease and neutropenia among the conditions Dr. Brem treats.

CMS data shows 842 Medicare services from Dr. Brem across 11 procedure codes in 2024, for 260 Medicare patients. Medicare paid $75,318 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 260 Medicare patients who saw Dr. Brem in 2024. The largest group is 65 to 74, with 111 patients. 74% of them have high blood pressure, and 70% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brem's median patient age at 66, with 49% women.

In 2024, Dr. Brem wrote 685 Medicare Part D claims for 106 patients. 72% of them were for generic drugs. CMS names the drug for 381 of them, across 19 drugs with 11 or more claims each, at $1,869,808 in total drug cost. In 2023, CMS named 234 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Brem for performance year 2024, reported through an alternative payment model (APM). Dr. Brem accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brem as offering telehealth.

Dmand AI links 29 papers to Dr. Brem, published from 2012 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse and Cyclophosphamide. Dr. Brem has published most often in J Emerg Med. Dr. Brem's most frequent co-authors are Alex Koyfman, MD, David J. Benjamin, MD and Danielle Megan Brazel, MD.

Dmand AI links Dr. Brem to 12 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell and Leukemia, B-Cell. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Brem that name 3 trials.

CMS Open Payments shows 355 general payments to Dr. Brem from 27 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. AstraZeneca Pharmaceuticals LP paid the most, $66,005. It also lists 6 research payments totaling $2,164 from 2022 to 2025, naming 3 clinical trials.

Dmand AI lists 14 awards for Dr. Brem, most recently Coltman Fellowship in 2021. Dr. Brem serves on ASH Publications Committee, SWOG Lymphoma Working Group and UC Hematologic Malignancies Consortium.

Dr. Brem graduated from Jacobs School of Medicine and Biomedical Sciences in 2010. Dr. Brem is a member of AOA, AACR, ASCO and ASH.

Dr. Brem is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.